Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.58 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21192401 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL5967470 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29362301 | 0.97 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29547181 | 0.97 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL2288397 | 0.97 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL436024 | 0.97 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL6158363 | 0.97 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29792115 | 0.97 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL31681399 | 0.97 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL23722974 | 0.94 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250304623-A1 | PEPTIDES FOR INTRACELLULAR DELIVERY | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2025-10-02 | — | — | US | disclosed |
| EP-4543900-A1 | PEPTIDES FOR INTRACELLULAR DELIVERY | Universidade de Santiago de Compostela (ES) | 2025-04-30 | — | — | EP | disclosed |
| CN-119768416-A | Peptides for intracellular delivery | 圣地亚哥-德孔波斯特拉大学 | 2025-04-04 | — | — | CN | disclosed |
| US-20240368227-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | OHIO STATE INNOVATION FOUNDATION | 2024-11-07 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023247781-A1 | PEPTIDES FOR INTRACELLULAR DELIVERY | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2023-12-28 | — | — | WO | disclosed |
| EP-4296274-A1 | PEPTIDES FOR INTRACELLULAR DELIVERY | Universidade de Santiago de Compostela (ES) | 2023-12-27 | — | — | EP | disclosed |
| US-20230382947-A1 | METHODS FOR PROXIMITY MEDIATED COUPLING OF A FIRST AGENT TO A SECOND AGENT | UNIVERSITEIT GENT (BE) | 2023-11-30 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4229069-A1 | METHODS FOR PROXIMITY MEDIATED COUPLING OF A FIRST AGENT TO A SECOND AGENT | Universiteit Gent (BE) | 2023-08-23 | — | — | EP | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| CN-115181157-A | Method for preparing disulfide bond-containing polypeptide by solid-liquid phase combination | 湖北健翔生物制药有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022079127-A1 | METHODS FOR PROXIMITY MEDIATED COUPLING OF A FIRST AGENT TO A SECOND AGENT | UNIVERSITEIT GENT (BE) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304623-A1 | PEPTIDES FOR INTRACELLULAR DELIVERY | LNPEP, TAP2, TMEM205 | MDM2 2881/4885MDM4 1328/4885TP53 292/4885 |
| US-20240368227-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | VIP, LNPEP, TAP1 | MDM2 3264/4885MDM4 1881/4885TP53 67/4885 |
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | MDM2 938/4885MDM4 1827/4885TP53 130/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | MDM2 4387/4885MDM4 3343/4885TP53 1476/4885 |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | MDM2 4122/4885MDM4 2568/4885TP53 1243/4885 |
| US-20230382947-A1 | METHODS FOR PROXIMITY MEDIATED COUPLING OF A FIRST AGENT TO A SECOND AGENT | DCLRE1A, CNBP, RNGTT | MDM2 915/4885MDM4 1969/4885TP53 903/4885 |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | VIP, LNPEP, TAP1 | MDM2 3264/4885MDM4 1881/4885TP53 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.